Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | HK1 | P19367 | 2/20 | 0.50 |
| ▸ | HKDC1 | Q2TB90 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 3/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19348432 | 0.90 | ALDH1A1 (0.49) | ALDH1A1HSD17B10HK1HKDC1MAPT | |
| SCHEMBL19348514 | 0.86 | ALDH1A1 (0.48) | ALDH1A1HSD17B10HK1HKDC1MAPT | |
| SCHEMBL19368938 | 0.85 | ALDH1A1 (0.47) | ALDH1A1HSD17B10HK1HKDC1MAPT | |
| SCHEMBL19348498 | 0.84 | ALDH1A1 (0.49) | ALDH1A1HSD17B10HK1HKDC1MAPT | |
| SCHEMBL19348405 | 0.83 | ALDH1A1 (0.45) | ALDH1A1HSD17B10HK1HKDC1MAPT | |
| SCHEMBL19348461 | 0.83 | ALDH1A1 (0.48) | ALDH1A1HSD17B10HK1HKDC1MAPT | |
| SCHEMBL19349023 | 0.81 | MAPT (0.43) | ALDH1A1HSD17B10HK1HKDC1MAPT | |
| SCHEMBL19361517 | 0.81 | ALDH1A1 (0.47) | ALDH1A1HSD17B10HK1HKDC1MAPT | |
| SCHEMBL19361513 | 0.81 | ALDH1A1 (0.47) | ALDH1A1HSD17B10HK1HKDC1MAPT | |
| SCHEMBL19348423 | 0.81 | MAPK7 (0.47) | ALDH1A1HSD17B10HK1HKDC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3191483-B1 | COMPOUNDS AS CRTH2 ANTAGONIST AND USES THEREOF | NORTH & SOUTH BROTHER PHARMACY INVESTMENT CO LTD (CN) | 2020-06-10 | — | — | EP | disclosed |
| EP-3191483-B1 | COMPOUNDS AS CRTH2 ANTAGONIST AND USES THEREOF | NORTH & SOUTH BROTHER PHARMACY INVESTMENT CO LTD (CN) | 2020-06-10 | — | — | EP | disclosed |
| US-9951010-B2 | Compounds as CRTH2 antagonist and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-04-24 | — | — | US | disclosed |
| US-9951010-B2 | Compounds as CRTH2 antagonist and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-04-24 | — | — | US | disclosed |
| US-9951010-B2 | Compounds as CRTH2 antagonist and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-04-24 | — | — | US | disclosed |
| US-20170267634-A1 | COMPOUNDS AS CRTH2 ANTAGONIST AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-09-21 | — | — | US | disclosed |
| US-20170267634-A1 | COMPOUNDS AS CRTH2 ANTAGONIST AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-09-21 | — | — | US | disclosed |
| US-20170267634-A1 | COMPOUNDS AS CRTH2 ANTAGONIST AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267634-A1 | COMPOUNDS AS CRTH2 ANTAGONIST AND USES THEREOF | HRH2, PTGDR2, HRH1 | ALDH1A1 1226/4885HSD17B10 831/4885HK1 1963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.